Application Scientist
About the job
- A Master's degree or Ph.D. in Chemistry, Biochemistry, or a related field is required.
- Experience in sample preparation, sample analysis, and data analysis for mass spectrometry imaging is required.
- At least 5 years of hands-on user experience in mass spectrometry imaging, including matrix-assisted laser desorption/ionization (MALDI)- or desorption electrospray ionization (DESI)-based imaging, is required.
- Strong oral and written communication skills are required.
- Good presentation skills are required.
- Ability to work in a fast-paced collaborative research environment is required.
- Ability to break down problems and projects into manageable tasks is required.
- Provide comprehensive technical support for mass spectrometry imaging, addressing user issues and challenges.
- Work with the global MALDI imaging team to translate Bruker technologies into locally relevant workflows that address biological questions.
- Plan and deliver seminars, workshops, and roadshows in Mandarin and fluent English, and own their technical content.
- Independently execute on-site or in-house demonstration experiments and advanced training courses.
- Design and execute complete mass spectrometry imaging workflows, including tissue preparation, matrix deposition, data processing, and demonstration report writing.
- Translate and culturally adapt global marketing collateral, including brochures, technical notes, and web content, while ensuring scientific accuracy and regulatory compliance for the Chinese market.
- Communicate regularly with factory product and marketing managers to develop China-specific marketing tactics and materials aligned with global strategy.
- Organize and conduct internal training for the sales team.
- Experience with Bruker mass spectrometry instrumentation is an advantage.
About the company
Bruker makes analytical and diagnostic instruments used by researchers and industries. Its products help analyze materials and biological samples to reveal chemical structure, composition, and properties, with notable roots in nuclear magnetic resonance (NMR) technology and a broad portfolio beyond that field. The company works by designing and selling instruments such as analytical tools that collect data from samples (for example, signals from nuclei in NMR or other spectroscopic methods) and provide insights to researchers. Bruker differentiates itself through a long history of developing advanced technologies, a focus on innovation in scientific instrumentation, and a global product range serving life sciences, materials science, and environmental analysis, supported by steady investment in research and development. Its goal is to equip researchers and industries with reliable tools to push the boundaries of what is possible in science and discovery.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Billerica, Massachusetts
Founded
1960
Get referred to Bruker
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 28, 2026 timsUltra AIP and timsOmni launches deepen proteomics and oligonucleotide workflows.
- August 10, 2026 MIMETAS deal expands Bruker into human-relevant drug discovery models.
- UC Berkeley ordered over $6 million of Bruker NMR systems, delivering 2027 revenue.
What critics are saying
- Bruker’s first-half 2026 organic revenue declined 0.8%, exposing fragile demand recovery.
- Academic spending stayed soft in 2026, while tariffs and currency pressured results.
- If MIMETAS and fusion remain niche, Bruker’s acquisition-heavy strategy destroys capital returns.
What makes Bruker unique
- Bruker owns timsTOF proteomics, NMR, microscopy, and microphysiological systems under one platform.
- Bruker’s August 31 XFlash 7200 FIRE raises SEM-EDS throughput beyond conventional detector designs.
- Bruker’s BEST superconductors supply ITER, Wendelstein 7-X, CERN, and fusion demonstrators.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Disability Insurance
Life Insurance
Dental Insurance
Flexible Work Hours
Employee Discounts
Growth & Insights and Company News
6 month growth
13%1 year growth
13%2 year growth
13%Bruker Corporation (Nasdaq: BRKR) today announced that it has completed the acquisition of PhenomeX, a leading provider of single-cell biology research tools...
Bruker advances functional proteomics with novel timsUltra AIP and timsOmni workflows for drug discovery & development and disease biology research. Sep 28 2026 12:00 BST * MultiDIA-PASEF significantly increases protein sequence coverage on timsUltra AIP * ProteoScape connects PASEF discovery with rapid prm-PASEF target validation * Spectronaut(R) AI transfer learning accelerates adaptation to new MS capabilities * Guided PASEF EXciD enables high-throughput glycopeptide characterization * Integrated HDX-MS workflows advance protein conformation and interaction studies * timsOmni(TM) enables RNA and DNA top-down structural and native RNA analysis SINGAPORE-(BUSINESS WIRE)-Sep. 28, 2026- At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF discovery with prm-PASEF target validation on the same timsTOF platform. Novel timsOmni and integrated HDX-MS workflows extend structural analysis to glycopeptides, proteins, and nucleic acids.
Bruker Corporation receives order from University of California, Berkeley for high-field nmr systems for major upgrade of Magnetic Resonance research infrastructure. Published on 09/21/2026 at 09:36 am EDT S&P Capital IQ Bruker Corporation announced a multi-system order from University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800 MHz?class instrumentation. The investment is centered on a Bruker AV NEO-X 800 MHz spectrometer equipped with a cryogenically cooled MAS CryoProbe, complemented by several additional NMR systems and upgrades supporting solid-state, solution-state and Dynamic Nuclear Polarization (DNP) research. The UC Berkeley NMR order exceeds USD 6 million and is expected to be delivered in 2027. (C) S&P Capital IQ - 2026
Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities
Unaudited Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023